PapersFlow Research Brief
Glaucoma and retinal disorders
Research Guide
What is Glaucoma and retinal disorders?
Glaucoma and retinal disorders refer to a cluster of eye conditions including glaucoma, characterized by optic nerve damage often linked to elevated intraocular pressure, retinal ganglion cell loss, and associated retinal diseases involving neurodegeneration, vascular changes, and visual field progression, with optical coherence tomography used for diagnosis and monitoring.
This field encompasses 156,112 papers on the global prevalence, treatment, and risk factors of glaucoma and retinal disorders. Key areas include intraocular pressure, optic nerve damage, ocular hypertension, and primary open-angle glaucoma. Optical coherence tomography provides noninvasive cross-sectional imaging of retinal microstructures.
Topic Hierarchy
Research Sub-Topics
Primary Open-Angle Glaucoma
This sub-topic examines the epidemiology, genetic risk factors, and progressive optic nerve damage in primary open-angle glaucoma, the most common form of glaucoma. Researchers investigate visual field progression patterns and long-term management strategies using intraocular pressure-lowering therapies.
Intraocular Pressure Regulation
This area focuses on the biomechanics of aqueous humor dynamics, trabecular meshwork function, and pharmacological modulation of intraocular pressure. Studies explore the relationship between ocular hypertension and glaucoma onset through clinical trials like the Ocular Hypertension Treatment Study.
Optical Coherence Tomography in Glaucoma
Researchers develop and validate OCT imaging techniques for quantifying retinal nerve fiber layer thinning and optic disc changes in glaucoma diagnosis and monitoring. This sub-topic covers structural-functional correlations and progression biomarkers using spectral-domain OCT.
Retinal Ganglion Cell Neurodegeneration
This sub-topic investigates molecular pathways of retinal ganglion cell apoptosis, axonal transport deficits, and neuroprotection strategies in glaucoma. Studies integrate animal models and human postmortem analyses to understand optic nerve head remodeling.
Visual Field Progression Modeling
Researchers analyze perimetry data to model rates and patterns of visual field loss, identifying risk factors for rapid progression in glaucoma patients. This includes statistical methods like pointwise linear regression and machine learning predictions.
Why It Matters
Glaucoma ranks as the second leading cause of blindness worldwide, disproportionately affecting women and Asians, with projections estimating increased burden through 2040 (Quigley 2006; Tham et al. (2014) in "Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040"). The Ocular Hypertension Treatment Study demonstrated that topical ocular hypotensive medication delays or prevents primary open-angle glaucoma onset in individuals with elevated intraocular pressure (Kass (2002) in "The Ocular Hypertension Treatment Study"). Vascular endothelial growth factor in ocular fluid mediates active intraocular neovascularization in ischemic retinal diseases like diabetic retinopathy and retinal vein occlusion (Aiello et al. (1994) in "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders"). These insights guide clinical referrals, medication adherence, and treatments reducing visual field progression across ophthalmology.
Reading Guide
Where to Start
"Optical Coherence Tomography" by Huang et al. (1991) is the first paper to read, as it introduces the foundational noninvasive imaging technique central to diagnosing and monitoring glaucoma and retinal disorders, with 13,493 citations establishing its core role.
Key Papers Explained
"Optical Coherence Tomography" (Huang et al. 1991) provides the imaging foundation enabling detailed retinal analysis, which Quigley (2006) in "The number of people with glaucoma worldwide in 2010 and 2020" uses to quantify global prevalence as the second leading blindness cause. Tham et al. (2014) in "Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040" extends this with 2040 projections, while Weinreb et al. (2014) in "The Pathophysiology and Treatment of Glaucoma" integrates pathophysiology and treatments like hypotensives. Kass (2002) in "The Ocular Hypertension Treatment Study" validates treatment efficacy, and Aiello et al. (1994) in "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders" connects vascular factors to retinal disorders, building a progression from diagnostics to epidemiology, mechanisms, and interventions.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints focus on deep learning for glaucoma detection from retinal fundus and 3D OCT images, including hybrid models for optic nerve analysis and probabilistic segmentation pipelines. Glaukos received FDA approval for iDose TR re-administration and Epioxa for corneal cross-linking. NIH Oculomics initiative develops novel ocular imaging with machine learning, while code repositories like Harvard-GDP offer multimodal datasets for progression forecasting.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Optical Coherence Tomography | 1991 | Science | 13.5K | ✕ |
| 2 | The number of people with glaucoma worldwide in 2010 and 2020 | 2006 | British Journal of Oph... | 7.3K | ✓ |
| 3 | Global Prevalence of Glaucoma and Projections of Glaucoma Burd... | 2014 | Ophthalmology | 6.6K | ✕ |
| 4 | Global Prevalence of Myopia and High Myopia and Temporal Trend... | 2016 | Ophthalmology | 5.0K | ✓ |
| 5 | The Pathophysiology and Treatment of Glaucoma | 2014 | JAMA | 3.8K | ✓ |
| 6 | Vascular Endothelial Growth Factor in Ocular Fluid of Patients... | 1994 | New England Journal of... | 3.7K | ✓ |
| 7 | The Ocular Hypertension Treatment Study | 2002 | Archives of Ophthalmology | 3.6K | ✓ |
| 8 | Proposed international clinical diabetic retinopathy and diabe... | 2003 | Ophthalmology | 3.6K | ✕ |
| 9 | Investigative Ophthalmology and Visual Science | 2010 | — | 3.4K | ✕ |
| 10 | Global causes of blindness and distance vision impairment 1990... | 2017 | The Lancet Global Health | 3.2K | ✓ |
In the News
Glaukos Announces US FDA Approval of NDA Supplement ...
today announced that the U.S. Food and Drug Administration (FDA) has approved an NDA labeling supplement allowing for re-administration of*iDose®TR*using a repeat treatment protocol. The FDA approv...
The £10000 Grant That could Change the Future of ...
## From early data to breakthrough discoveries With continued funding, Dr Mead’s team began exploring how microRNA behave in glaucoma.
Glaukos Announces FDA Approval of Epioxa
announced today the U.S. Food and Drug Administration (FDA) approved its Epioxa™ HD / Epioxa™ (“Epioxa”) New Drug Application (NDA). Epioxa is a groundbreaking advancement in corneal cross-linking ...
New research shows promise in restoring vision
New research suggests a path forward that could change the lives of millions around the world. It may lead to a breakthrough for people who are losing vision due to retinal damage and conditions li...
Oculomics | NIH Common Fund
The Common Fund Development and Application of Imaging Technologies for Oculomics**(Oculomics)**Venture Initiative aims to support development and application of novel, noninvasive ocular (eye) ima...
Code & Tools
This project implements a complete machine learning pipeline for glaucoma detection from retinal fundus images. The pipeline is built with modern l...
Code for "Leveraging Probabilistic Segmentation Models for Improved Glaucoma Diagnosis: A Clinical Pipeline Approach" MIDL 2024.
Medical artificial intelligence (AI) offers great potential for recognizing signs of health conditions in retinal images and expediting the diagnos...
## Repository files navigation # SpatialOCT-Glaucoma This repository contains the implementation of the paper entitled "Spatial-aware Transformer...
Glaucoma is the number one cause of irreversible blindness globally. A major challenge for accurate glaucoma detection and progression forecasting ...
Recent Preprints
Intelligent retinal disease detection using deep learning
* **Glaucoma** 9 **:**Glaucoma is an eye condition characterized by damage to the optic nerve, which transmits visual information from the eye to the brain. This damage is often associated with ele...
JAMA Ophthalmology – Innovative Research in Vision ...
Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control * 82Citations Assessment of a Large Language Model’s Responses to Questions and Cases About Glaucoma and Retina Management * 78Cit...
Advancements in Deep Learning for Glaucoma Detection from ...
potential in automating glaucoma detection from retinal fundus images with high accuracy and minimal expert intervention. This review presents a comprehensive analysis of recent DL-based approaches...
Identifying glaucoma with deep learning by utilizing the ...
improving computational efficiency • Open-source code release supports reproducibility and deployment Abstract Glaucoma is a leading cause of irreversible vision loss, and its timely detection rema...
Glaucoma articles within Scientific Reports
- Pei-Yao Chang - , Jiun-Yi Wang - & Jia-Kang Wang - Article 14 March 2025\| Open Access - Weichen Xu - , Qinglu Fan - & Changzheng Chen - Article 07 March 2025\| Open Access - Pushpa R...
Latest Developments
Recent developments in glaucoma and retinal disorders research as of February 2026 include promising innovations such as sustained-release medications and laser therapies for glaucoma, as well as regenerative approaches like stem cell therapy for optic nerve and retinal cell regeneration (Ophthalmology Times, CCTeyes). Additionally, advances in retinal prosthetics, such as the photovoltaic retina implant system, have shown significant improvements in restoring vision in geographic atrophy due to age-related macular degeneration (NEJM). Research efforts also focus on regenerative therapies, including gene identification for retinal ganglion cell regeneration inspired by zebrafish models, and new scientific appointments aim to boost glaucoma and inherited retinal disease research programs (BrightFocus, Glaucoma Australia). Furthermore, pharmacological studies indicate neuroprotective effects of drugs like metformin and SGLT2 inhibitors on retinal cells and glaucoma risk (Cell Death Discovery, Scientific Reports).
Sources
Frequently Asked Questions
What is optical coherence tomography?
"Optical Coherence Tomography" by Huang et al. (1991) describes a noninvasive technique using low-coherence interferometry for cross-sectional imaging of optical scattering in biological tissue microstructures. It produces two-dimensional images analogous to ultrasound but with light. This method enables detailed retinal and optic nerve assessment in glaucoma monitoring.
How many people had glaucoma worldwide in 2010 and 2020?
"The number of people with glaucoma worldwide in 2010 and 2020" by Quigley (2006) establishes glaucoma as the second leading cause of blindness globally. It disproportionately impacts women and Asians. The paper quantifies prevalence for these years to inform public health planning.
What role does vascular endothelial growth factor play in retinal disorders?
"Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders" by Aiello et al. (1994) shows elevated VEGF levels in ocular fluid of patients with ischemic retinal diseases. VEGF mediates active intraocular neovascularization in diabetic retinopathy and retinal vein occlusion. These findings link VEGF to pathological vascular growth in retinal conditions.
What did the Ocular Hypertension Treatment Study find?
"The Ocular Hypertension Treatment Study" by Kass (2002) found topical ocular hypotensive medication effective in delaying or preventing primary open-angle glaucoma in elevated IOP individuals. Clinicians should consider treatment for those at risk, though not all borderline cases require it. This supports targeted intervention based on IOP levels.
What is primary open-angle glaucoma?
Primary open-angle glaucoma involves optic nerve damage and visual field progression often due to elevated intraocular pressure or ocular hypertension. Papers like "The Pathophysiology and Treatment of Glaucoma" by Weinreb et al. (2014) emphasize early diagnosis via optic nerve head examination and medication adherence. Risk factors include family history and neurodegeneration of retinal ganglion cells.
How is glaucoma prevalence projected?
"Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040" by Tham et al. (2014) provides estimates of current global prevalence and future increases. It highlights the growing burden due to aging populations. These projections aid in resource allocation for diagnosis and treatment.
Open Research Questions
- ? How can deep learning models improve glaucoma detection accuracy from diverse retinal fundus images across varying quality datasets?
- ? What mechanisms underlie retinal ganglion cell neurodegeneration in normal-tension glaucoma?
- ? Which multimodal imaging approaches best predict glaucoma progression beyond intraocular pressure measures?
- ? How do microRNA pathways influence optic nerve damage in glaucoma, and can they be targeted therapeutically?
- ? What factors drive visual field progression rates in primary open-angle glaucoma patients on hypotensive therapy?
Recent Trends
Deep learning advancements automate glaucoma detection from fundus images and OCT, with preprints like "Intelligent retinal disease detection using deep learning" and "Advancements in Deep Learning for Glaucoma Detection from ..." emphasizing high-accuracy segmentation of optic disc/cup using datasets like ACRIMA and Drishti-GS1. Glaukos FDA approvals include iDose TR repeat treatment and Epioxa (2025).
2026GitHub tools such as Harvard-Ophthalmology-AI-Lab/Harvard-GDP provide multimodal datasets for semi-supervised progression prediction, reflecting a shift toward AI-driven diagnostics amid stable 156,112 paper counts.
Research Glaucoma and retinal disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Glaucoma and retinal disorders with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers